ReviewJournal of assisted reproduction and genetics2016
Pre-implantation genetic testing in ART: who will benefit and what is the evidence?
Review in Journal of assisted reproduction and genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global transcriptomic changes occur in uterine fluid-derived extracellular vesicles during the endometrial window for embryo implantation.Human reproduction (Oxford, England) · 2021Pooled it
- Trial
- Single best euploid versus single best unknown-ploidy blastocyst frozen embryo transfers: a randomized controlled trial.Journal of assisted reproduction and genetics · 2019Trial
- Preimplantation genetic testing for male factor infertility: lights and shadows.Journal of endocrinological investigation · 2026Review
- Double vitrification-warming cycles coupled with one blastocyst biopsy do not affect the chance of live birth after an euploid blastocyst transfer: a propensity score matching study.Journal of translational medicine · 2025Article
- Endometrial receptivity profiled through transcriptomic analysis of uterine fluid extracellular vesicles using systems biology and bayesian modeling for pregnancy prediction.Scientific reports · 2025Article
- Article
- Pre-implantation genetic diagnosis in an Iranian family with a novel mutation in MUT gene.BMC medical genetics · 2020Article
- Stem cells and reproduction.BMB reports · 2019Review
- Transient Sperm Starvation Improves the Outcome of Assisted Reproductive Technologies.Frontiers in cell and developmental biology · 2019Article
- Euploid embryos selected by an automated time-lapse system have superior SET outcomes than selected solely by conventional morphology assessment.Journal of assisted reproduction and genetics · 2018Article
- Contraction behaviour reduces embryo competence in high-quality euploid blastocysts.Journal of assisted reproduction and genetics · 2018Article
- Assisted hatching and live births in first-cycle frozen embryo transfers.Fertility and sterility · 2017Article
- Predictive value of spindle retardance in embryo implantation rate.Journal of assisted reproduction and genetics · 2017Article
- Excellence in assisted reproductive technologies: clinical and laboratory perspectives.Journal of assisted reproduction and genetics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-implantation genetic diagnosis for aneuploidy testing (PGD-A) is a tool to identify euploid embryos during IVF. The suggested populations of patients that can benefit from it are infertile women of advanced maternal age, with a history of recurrent miscarriages and/or IVF failures. However, a general consensus has not yet been reached.After the clinical failure of its first version based on cleavage stage biopsy and 9 chromosome-FISH analysis, PGD-A is currently performed by 24 chromosome screening techniques on trophectoderm (TE) biopsies. This approach has been clearly demonstrated to involve a higher clinical efficiency with respect to the standard care, in terms of sustained pregnancy rate per transfer and lower miscarriage rate. However, data about PGD-A efficacy calculated on a per intention-to-treat basis, as well as an analysis of its cost-effectiveness, are still missing.TE biopsy is a safe and extensively validated approach with low biological and technical margin of error. Firstly, the prevalence of mosaic diploid/aneuploid blastocysts is estimated to be between 0 and 16 %, thus largely tolerable. Secondly, all the comprehensive chromosome screening (CCS) technologies adapted to, or designed to conduct PGD-A are highly concordant, and qPCR in particular has been proven to show the lowest false positive error rate (0.5 %) and a clinically recognizable error rate per blastocyst of just 0.21 %.In conclusion, there is a sufficient body of evidence to support the clinical application of CCS-based PGD-A on TE biopsies. The main limiting factor is the need for a high-standard laboratory to conduct blastocyst culture, biopsy and vitrification without impacting embryo viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.